The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era

Critical Reviews in Oncology/Hematology

Volumn 79, Issue 2, 2011, Pages 135-143

  Breccia, Massimo ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chronic myeloid leukemia; Imatinib; Molecular response

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; IMATINIB; PEGINTERFERON;

CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LOW DRUG DOSE; MINIMAL RESIDUAL DISEASE; MONITORING; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STANDARDIZATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; DRUG ADMINISTRATION SCHEDULE; FUSION PROTEINS, BCR-ABL; HUMANS; INTERFERON-GAMMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; RNA, MESSENGER; SURVIVAL RATE; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 79960165168     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.07.003     Document Type: Review

References (47)

1. Faderl S., Talpaz M., Estrov Z., et al. Chronic myelogenous leukaemia: biology and therapy. Ann Intern Med 1999, 131:207-219.
2. Goldman J.M., Melo J.V. Chronic myeloid leukaemia-advances in biology and new approaches to treatment. N Engl J Med 2003, 349:1451-1464.
3. Sattler M., Griffin J.D. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003, 40:4-10.
4. Donato N.J., Wu J.Y., Stapley J., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukaemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
5. Deininger M., Buchdunger E., Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105:2640-2653.
6. Druker B.J., Guilhot F., O'Brien S., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
7. Kantarjian H., O'Brien S., Shan J., et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?. Cancer 2008, 115:837-845.
8. de Lavallade H., Apperley J.F., Khorashad J.S., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008, 26:3358-3363.
9. Hughes T.P., Kaeda J., Branford S., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432.
10. Hochhaus A. Minimal residual disease in chronic myeloid leukaemia patients. Best Pract Clin Haematol 2002, 15:159-178.
11. Hochhaus A., Weisser A., La Rosée P., et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000, 14:998-1005.
12. Serrano J., Roman J., Sanchez J., et al. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse. Blood 2000, 95:2659-2665.
13. Olavarria E., Craddock C., Dazzi F., et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002, 99:3861-3862.
14. Hughes T., Deininger M., Hochhaus A., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
15. Branford S., Fletcher L., Cross N.C., et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008, 112:3330-3338.
16. Baccarani M., Cortes J., Pane F., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
17. Müller M.C., Cross N.C., Erben P., et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009, 23:1957-1963.
18. Deininger M.W., O'Brien S.G., Guilhot F., et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009, 114:1126.
19. Hughes T.P., Hochhaus A., Branford S., et al. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on Imatinib (IM) at 72 mo: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML-CP). Blood 2008, 112. abstr 334.
20. Hughes T.P., Branford S., White D.L., et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600mg/day of imatinib as initial therapy. Blood 2008, 112:3965-3973.
21. Castagnetti F., Palandri F., Amabile M., et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood 2009, 113:3428-3434.
22. Cortes J.E., Kantarjian H.M., Goldberg S.L., et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 2009, 27:4754-4759.
23. Guilhot F., Mahon F.X., Guilhot J., et al. Randomized comparison of imatinib versus imatinib combination therapies in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (CP): first results of the phase III (SPIRIT) trial from the French CML Group (FI LMC). Blood 2008, 112:183.
24. Baccarani M., Rosti G., Castagnetti F., et al. Comparison of imatinib 400mg and 800mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009, 113:4497-4504.
25. Cortes J.E., Baccarani M., Guilhot F., et al. Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010, 28:424-430.
26. Palandri F., Iacobucci I., Castagnetti F., et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. Haematologica 2008, 93:770-777.
27. Merx K., Müller M.C., Kreil S., et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002, 16:1579-1583.
28. Wang L., Perason K., Ferguson J.E., Clark R.E. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 2003, 120:990-999.
29. Martinelli G., Iacobucci I., Rosti G., et al. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. Ann Oncol 2006, 17:495-502.
30. Cortes J., Talpaz M., O'Brien S., et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005, 11:3425-3432.
31. Press R.D., Love Z., Tronnes A.A., et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 2006, 107:4250-4256.
32. Branford S., Rudzki Z., Harper A., et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003, 17:2401-2409.
33. Muller M.C., Hanfstein B., Erben P., et al. Molecular response to first line imatinib therapy is predictive for long term event free survival in patients with chronic phase chronic myelogenous leukemia-an interim analysis of the randomized German CML Study IV. Blood 2008, 112:333.
34. Press R.D., Galderisi C., Yang R., et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 2007, 13:6136-6143.
35. Branford S., Seymour J.F., Grigg A., et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007, 13:7080-7085.
36. Iacobucci I., Saglio G., Rosti G., et al. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 2006, 12:3037-3042.
37. Marin D., Milojkovic D., Olavarria E., et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008, 112:4437-4444.
38. Palandri F., Iacobucci I., Soverini S., et al. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. Clin Cancer Res 2009, 15:1059-1063.
39. Kantarjian H.M., Shan J., Jones D., et al. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol 2009, 27:3659-3663.
40. Marin D., Khorashad J.S., Foroni L., et al. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?. Br J Haematol 2009, 145:373-375.
41. Rousselot P., Huguet F., Rea D., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007, 109:58-60.
42. Ross D.M., Grigg A., Schwarer A., et al. The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR, and any relapses occur early. Blood 2008, 112:1102.
43. Mahon F.X., Rea D., Guilhot F., et al. Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients. Blood 2009, 114:859.
44. Branford S., Rudzki Z., Parkinson I., et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004, 104:2926-2932.
45. Wang L., Knight K., Lucas C., Clark R.E. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 2006, 91:235-239.
46. O'Brien S., Berman E., Borghaei H., et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw 2009, 7:984-1023.
47. Press R.D., Willis S.G., Laudadio J., Mauro M.J., Deininger M.W. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 2009, 114:2598-2605.